A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

Optic Neuropathy, Ischemic Clinical Trial

Official title:
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION

Status Completed

Clinical Trial Summary

The objective of this non-interventional study is to examine whether use of Phosphodiesterase Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset of acute NAION.

Clinical Trial Description

Sites will identify patients who meet the entry criteria during the conduct of their normal practice. Patients meeting these criteria will be offered participation in the study after reading and completing an informed consent document. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00759174
Study type	Observational
Source	Pfizer
Contact
Status	Completed
Phase
Start date	November 2008
Completion date	October 2012

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT02329288` - Retrobulbar Triamcinolone Acetonide Injection in the Treatment of NA-AION	Phase 3
Not yet recruiting	`NCT05749094` - Optic Nerve Sheath Ultrasound in Giant Cell Arteritis
Withdrawn	`NCT01607671` - Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%	Phase 1
Completed	`NCT00404729` - Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases	Phase 4